NexgenRx Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was CAD 3.32 million compared to CAD 2.86 million a year ago. Net loss was CAD 0.064605 million compared to net income of CAD 0.429581 million a year ago. Basic loss per share from continuing operations was CAD 0.001 compared to basic earnings per share from continuing operations of CAD 0.006 a year ago. Diluted loss per share from continuing operations was CAD 0.001 compared to diluted earnings per share from continuing operations of CAD 0.006 a year ago.
For the nine months, revenue was CAD 9.4 million compared to CAD 8.43 million a year ago. Net income was CAD 0.343419 million compared to CAD 1.17 million a year ago. Basic earnings per share from continuing operations was CAD 0.005 compared to CAD 0.017 a year ago. Diluted earnings per share from continuing operations was CAD 0.005 compared to CAD 0.016 a year ago.